Rinvoq and Benign neoplasm - a phase IV clinical study of FDA data

Summary:

Benign neoplasm is reported as a side effect among people who take Rinvoq (upadacitinib), especially for people who are female, 60+ old, also take Potassium, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Benign neoplasm when taking Rinvoq. It is created by eHealthMe based on reports of 47,330 people who have side effects when taking Rinvoq from the FDA, and is updated regularly.

What is Rinvoq?

Rinvoq has active ingredients of upadacitinib. eHealthMe is studying from 47,375 Rinvoq users. Check the latest studies of Rinvoq.

What is Benign neoplasm?

Benign neoplasm (benign (non-cancerous) tumour) is found to be associated with 209 drugs and 283 conditions by eHealthMe. Check the latest studies of Benign neoplasm.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

47,330 people reported to have side effects when taking Rinvoq.
Among them, 13 people (0.03%) have Benign neoplasm.

Among these 13 people:

What is the gender of people who have Benign neoplasm when taking Rinvoq? *

female: 84.62 %
male: 15.38 %

What is the age of people who have Benign neoplasm when taking Rinvoq? *

What are other drugs people take besides Rinvoq? *

What are other side effects people have besides Benign neoplasm? *

High Blood Cholesterol: 3 people, 23.08%
Peripheral Swelling: 2 people, 15.38%
Cyst (a closed sac): 2 people, 15.38%
Fatigue (feeling of tiredness): 2 people, 15.38%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 7.69%
Arthropathy: 1 person, 7.69%
Aspartate Aminotransferase Increased: 1 person, 7.69%
Blood Iron Decreased: 1 person, 7.69%
Gastrointestinal Bacterial Infection (infection of the stomach and intestines caused by bacteria): 1 person, 7.69%
Bone Deformity: 1 person, 7.69%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 69.23%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 7.69%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Rinvoq and have Benign neoplasm?

- Check whether Benign neoplasm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rinvoq:

Rinvoq (47,375 reports)

Benign neoplasm treatments and more:

Benign neoplasm (1,580 reports)

Browse all side effects of Rinvoq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Benign neoplasm:

Benign neoplasm (209 drugs)

Browse all the conditions that are associated with Benign neoplasm:

Benign neoplasm (283 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on upadacitinib (the active ingredients of Rinvoq) and Rinvoq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.